MSCs derived from patients with acute myeloid leukemia (AML), but not normal MSCs, highly express p53, suggesting that the p53 pathway is active in the leukemia microenvironment [16], although the extent to which p53 activity in MSCs is relevant to AML progression is poorly understood. Here, TP53 is linked to leukemia.